The reform announced in February 2025 profoundly transforms the framework for managing wheelchairs in France. By placing full reimbursement by Health Insurance at the heart of the system, the government is putting an end to a fragmented and complex system that, until now, limited patients' access to equipment that is nevertheless essential to their independence.
For professionals in the health and social care sector, distributors, pharmacists, and prescribers, this reform represents a paradigm shift: it redefines processes, clarifies responsibilities, and reinforces quality and compliance requirements.
1. A public health reform with structural impacts
Until 2024, obtaining a wheelchair involved a combination of funding providers (Health Insurance, PCH, departmental funds, etc.), resulting in long delays, redundant procedures, and out-of-pocket expenses that could reach several thousand euros.
The government now recognizes that the wheelchair is an essential medical device, inseparable from the mobility, social participation, and dignity of people with disabilities.
The reform enacted in 2025 guarantees:
- full coverage,
- a single piece of funding provided by the National Health Insurance,
- a significant reduction in lead times,
- fair access to compliant and high-performing devices.
This development responds to a public health imperative: to simplify and secure a process that had become too burdensome for users and insufficiently clear for professionals.
2. A single payer: a major step forward for patients and medical device stakeholders
The central pillar of the reform is based on the creation of a single point of contact provided by the Health Insurance fund, which becomes the sole financier of wheelchairs (manual, electric, folding, specific, or sports).
Specifically:
- administrative procedures are unified,
- processing times are getting shorter,
- options and add-ons can be supported via DAP,
- The reading of the regulatory framework is simplified for professionals.
This model standardizes the processing of applications across the entire territory and limits the disparities that could exist between departments or funding structures.
3. Strengthening quality and compliance requirements
The reform is not limited to a financial evolution. It is accompanied by a revision of the specifications for reimbursable wheelchairs, conducted with the French National Authority for Health (HAS), manufacturers, and user associations.
Objectives:
- ensure that the chairs distributed on the French market comply with higher standards of performance, durability, and safety,
- accelerate access to technological innovations,
- structuring a more sustainable supply chain, notably through the valorization of armchairs restored to good working condition (RBEU).
This requirement reinforces the role of stakeholders involved in medical device quality, including Smart Agents Healthcare.
4. A smoother, more structured user journey focused on efficiency
From now on, the customer journey is structured into clear steps:
- Needs assessment and testing by a healthcare professional.
- Prescription and prior agreement request (response within 2 months, silence = agreement).
- Chair provision, adjustments and training.
- Simplified renewal and enhanced repair package.
For distribution structures, this simplified framework allows for better logistical anticipation, a reduction in administrative disputes, and increased fluidity in the support chain.
5. Integration of sports wheelchairs: a reinforced inclusive dimension
The reform also extends coverage to wheelchairs intended for sports activities, which until now have been very poorly reimbursed.
- Standard models now benefit from a reimbursement increased to 2 400 €,
- Custom or more technical models are eligible via DAP.
This measure contributes to the development of adapted sports and extends the legacy of the Paris 2024 Paralympic Games.
6. What is the impact for pharmacies, home medical equipment providers (PSAD), and distributors?
The reform represents a structuring opportunity for market players:
- increase in demand, thanks to the full refund,
- clarification of relations with prescribers and the National Health Insurance,
- standardization of procedures,
- upgrading of the listed products,
- promotion of certified devices (CE MDR, ISO 7176, UN38.3 battery, etc.).
The actors capable of offering reliable, compliant, and immediately available solutions will be the best positioned.
7. The Smart Agents Healthcare foldable electric wheelchair: a model compliant with the reform requirements
The foldable electric wheelchair Smart Agents Healthcare fully meets the established criteria:
- CE MDR compliance,
- complete ISO 7176 tests,
- UN38.3 certified lithium battery,
- indoor and outdoor mixed use,
- autonomy and stability adapted to new standards,
- ergonomics optimized for the user and caregiver.
It fits naturally into the new full reimbursement framework and is a reliable solution for pharmacists, home medical equipment providers, and distributors.
Conclusion: a structural reform, a strengthened sector
With this ambitious reform, France is taking a decisive step toward a more inclusive society and a more coherent healthcare system.
For users, this is the end of a complex process and of often unsustainable out-of-pocket costs.
For healthcare professionals and distributors, this is an opportunity to strengthen service quality, process clarity, and the availability of higher-performing devices.
Smart Agents Healthcare is fully aligned with this new dynamic, offering a range of compliant, reliable armchairs tailored to the needs of the French market.